Affibody-based molecular probe 99mTc-(HE)3ZHER2:V2 for non-invasive HER2 detection in ovarian and breast cancer xenografts

被引:0
|
作者
Hu, Xianwen [1 ]
Hu, Hongyu [1 ]
Li, Dandan [2 ]
Wang, Pan [1 ]
Cai, Jiong [1 ]
机构
[1] Zunyi Med Univ, Affiliated Hosp, Dept Nucl Med, 149 Dalian Rd, Zunyi 563003, Peoples R China
[2] Zunyi Hosp Tradit Chinese Med, Dept Obstet, Zunyi 563003, Guizhou, Peoples R China
来源
OPEN MEDICINE | 2024年 / 19卷 / 01期
关键词
human epidermal growth factor receptor 2; affibody; SPECT imaging; ovarian cancer; Tc-99m; BIODISTRIBUTION;
D O I
10.1515/med-2024-1027
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose- This study aimed to assess the biodistribution and bioactivity of the affibody molecular probe Tc-99m-(HE)(3)Z(HER2:V2), prepared by genetic recombination, and to investigate its potential for targeted human epidermal growth factor receptor 2 (HER2) imaging in SKOV3 ovarian cancer and MDA-MB-361 breast cancer xenografts. Methods- Affibody molecules were generated through genetic recombination. The radiochemical purity of the Tc-99m-labeled HER2 affibody was determined using reverse phase high performance liquid chromatography (RP-HPLC). Evaluation of HER2 affinity in SKOV3 ovarian cancer cells and MDA-MB-361 breast cancer cells (HER2-positive) was conducted by calculating equilibrium dissociation constants. Biodistribution of the Tc-99m-labeled affibody molecular probe was assessed in Balb/c mice bearing SKOV3 tumors. Tumor targeting specificity was evaluated in Balb/c mice using SKOV3, MDA-MB-361, and AT-3 (HER2-negative) xenografts. Results- Affibody (HE)(3)Z(HER2:V2), generated through recombinant gene expression, was successfully labeled with Tc-99m, achieving a radiochemical purity of (96.0 +/- 1.7)% (n = 3) as determined by RP-HPLC. This molecular probe exhibited specific binding to HER2-positive SKOV3 cells, demonstrating intense radioactive uptake. Biodistribution analysis showed rapid accumulation of Tc-99m-(HE)(3)Z(HER2:V2) in HER2-positive tumors post-administration, primarily clearing through the urinary system. Single-photon emission computed tomography imaging conducted 1-3 h after intravenous injection of Tc-99m-(HE)(3)Z(HER2:V2) into HER2-positive SKOV3 and MDA-MB-361 nude mouse models confirmed targeted uptake of the molecular probe by the tumors. Conclusions- The molecular probe Tc-99m-(HE)(3)Z(HER2:V2) developed in this study effectively targets HER2 for imaging HER2-positive SKOV3 and MDA-MB-361 xenografts in vivo. It exhibits rapid blood clearance without evident toxic effects, suggesting its potential as a valuable marker for detecting HER2 expression in tumor cells.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Radiosynthesis, optimization and pharmacokinetic study of the 99mTc-labeled human epidermal growth factor receptor 2 affibody molecule probe 99mTc-(HE)3ZHER2:V2
    Hu, Xianwen
    Liang, Zhigang
    Qi, Lili
    Li, Fangming
    Cai, Xiaojia
    Cai, Jiong
    NUCLEAR MEDICINE COMMUNICATIONS, 2023, 44 (04) : 244 - 251
  • [2] Non-Invasive Monitoring of HER2 Expression in Breast Cancer Patients with 99mTc-Affibody SPECT/CT
    Cai, Jiong
    Li, Xin
    Mao, Feng
    Wang, Pan
    Luo, Yaping
    Zheng, Kun
    Li, Fang
    Zhu, Zhaohui
    IRANIAN JOURNAL OF RADIOLOGY, 2020, 17 (01)
  • [3] Non-invasive Detection of HER2 Expression by Al18F-NOTA-HER2 Affibody in Gastric Cancer Xenografts
    Han, Jingya
    Zhao, Xinming
    Chen, Yang
    Zhang, Jingmian
    Wang, Jianfang
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [4] Characterization of 99mTc Labeled ZHER2: V2 Affibody Molecule for Imaging HER2-overexpression Tumors
    Zhao, Xinming
    Xing, Yu
    Yang, Yang
    Yu, Tianying
    Zhang, Jingmian
    Wang, Jianfang
    Zhang, Zhaoqi
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [5] 99mTc-maEEE-ZHER2:342, an affibody molecule-based tracer for the detection of HER2 expression in malignant tumors
    Tran, Thuy
    Engfeldt, Torun
    Orlova, Anna
    Sandstroem, Mattias
    Feldwisch, Joachim
    Abrahmsen, Lars
    Wennborg, Anders
    Tolmachev, Vladimir
    Karlstroem, Amelie Eriksson
    BIOCONJUGATE CHEMISTRY, 2007, 18 (06) : 1956 - 1964
  • [6] Phase I Trial of 99mTc-(HE)3-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer
    Bragina, Olga
    Chernov, Vladimir
    Schulga, Alexey
    Konovalova, Elena
    Garbukov, Eugeniy
    Vorobyeva, Anzhelika
    Orlova, Anna
    Tashireva, Liubov
    Sorensen, Jens
    Zelchan, Roman
    Medvedeva, Anna
    Deyev, Sergey
    Tolmachev, Vladimir
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (04) : 528 - 535
  • [7] Preclinical evaluation of 99mTc direct labeling ZHER2:V2 for HER2 positive tumors imaging
    Yang, Yang
    Zhao, Xinming
    Xing, Yu
    Yu, Tianying
    Zhang, Jingmian
    Wang, Jianfang
    ONCOLOGY LETTERS, 2018, 16 (04) : 5361 - 5366
  • [8] Preclinical Evaluation of 99mTc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake
    Oroujeni, Maryam
    Rinne, Sara S.
    Vorobyeva, Anzhelika
    Loftenius, Annika
    Feldwisch, Joachim
    Jonasson, Per
    Chernov, Vladimir
    Orlova, Anna
    Frejd, Fredrik Y.
    Tolmachev, Vladimir
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (05) : 1 - 20
  • [9] 188Re-ZHER2:V2, a Promising Affibody-Based Targeting Agent Against HER2-Expressing Tumors: Preclinical Assessment
    Altai, Mohamed
    Wallberg, Helena
    Honarvar, Hadis
    Strand, Joanna
    Orlova, Anna
    Varasteh, Zohreh
    Sandstrom, Mattias
    Lofblom, John
    Larsson, Erik
    Strand, Sven-Erik
    Lubberink, Mark
    Stahl, Stefan
    Tolmachev, Vladimir
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (11) : 1842 - 1848
  • [10] HER2-Targeted Affibody Molecule 99mTc-ABH2 for Imaging HER2 Expression in Breast Cancer
    Jin, Xiaona
    Zhang, Yuwei
    Cao, Xi
    Wang, Peipei
    Ren, Chao
    Cai, Jiong
    Wang, Xuefei
    Jing, Hongli
    Sun, Qiang
    Li, Fang
    CLINICAL NUCLEAR MEDICINE, 2025, 50 (01) : 25 - 30